Other Information
−Removed: Membership Interest Purchase Agreement entered into October 11, 2022, by and among Pasithea Therapeutics Corp., AlloMek Therapeutics, LLC, and certain Sellers (as defined in the agreement).
−Removed: (incorporated by reference to exhibit 2.1 of the Company’s Form 8-K filed with the Commission on October 12, 2022)
−Removed: Employment Agreement with Daniel Schneiderman
Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Inline XBRL Instance Document.
6 unchanged sentences
* Filed herewith.
−Removed: Furnished herewith.
+Added: ** Furnished, not filed
Pursuant to the requirements
6 unchanged sentences
(Principal Executive Officer)
−Removed: November 14, 2022
/s/ Daniel Schneiderman
3 unchanged sentences
Principal Accounting Officer)
−Removed: November 14, 2022
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.